Ticker >

Welcure Drugs&Pharma share price

Welcure Drugs & Pharmaceuticals Ltd.

BSE: 524661 SECTOR: Trading  18k   69   3

4.87
0 0
BSE: 26 Apr 04:00 PM

Price Summary

Today's High

₹ 4.88

Today's Low

₹ 4.87

52 Week High

₹ 5.48

52 Week Low

₹ 3.2

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

6.58 Cr.

Enterprise Value

6.58 Cr.

No. of Shares

1.35 Cr.

P/E

601.23

P/B

4.59

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  1.06

CASH

0 Cr.

DEBT

0 Cr.

Promoter Holding

0 %

EPS (TTM)

₹  0.01

Sales Growth

-100%

ROE

12.65 %

ROCE

12.67%

Profit Growth

331.41 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-100%
3 Year-100%
5 Year-100%

Profit Growth

1 Year331.41%
3 Year134.05%
5 Year48.59%

ROE%

1 Year12.65%
3 Year57.81%
5 Year28.36%

ROCE %

1 Year12.67%
3 Year57.91%
5 Year28.6%

Debt/Equity

0

Price to Cash Flow

61.57

Interest Cover Ratio

703.024154589372

CFO/PAT (5 Yr. Avg.)

0.915526009498743

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 0 0
Dec 2023 0 0
Sep 2023 0 0
Jun 2023 0 0
Mar 2023 0 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 57.8071635542343% over the past 3 years.
  • Company has been maintaining healthy ROCE of 57.9102785060812% over the past 3 years.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 0 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.54752425675046.

 Limitations

  • The company has shown a poor revenue growth of -100% for the Past 3 years.
  • Company has contingent liabilities of 0.329914 Cr.
  • The company is trading at a high PE of 601.23.
  • The company is trading at a high EV/EBITDA of 225.5308.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 0 0 0 0 0.04
Total Expenditure 0.01 0.05 0.03 0.09 0.06
Operating Profit -0.01 -0.05 -0.03 -0.09 -0.02
Other Income 0.01 0.22 0 0 0
Interest 0 0 0 0 0
Depreciation 0 0 0 0.01 0.01
Exceptional Items 0 0 0 0 0
Profit Before Tax 0 0.17 -0.03 -0.1 -0.03
Tax 0 0 0 0 0
Profit After Tax 0 0.17 -0.03 -0.1 -0.03
Adjusted EPS (Rs) 0 0.12 -0.03 -0.07 -0.02

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 0.08 0.08 0.13 0.11 0
Total Expenditure 0.08 0.09 0.08 0.08 0.13
Operating Profit 0 -0.01 0.06 0.02 -0.13
Other Income 0 0 0 0 0.24
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax 0 -0.01 0.06 0.02 0.1
Tax 0 0 0 0 0
Net Profit 0 -0.01 0.06 0.02 0.1
Adjusted EPS (Rs.) 0 -0.01 0.05 0.02 0.08

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 12.12 12.12 12.12 12.12 13.44
Total Reserves -12.09 -12.1 -12.05 -12.03 -11.92
Borrowings 0 0 0 0 0
Other N/C liabilities 0 0 0 0 0
Current liabilities 0.01 0.01 0 0 0.01
Total Liabilities 0.03 0.02 0.07 0.1 1.53
Assets
Net Block 0 0 0 0 0.06
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0.17
Loans & Advances 0 0 0 0.03 1.3
Other N/C Assets 0 0 0 0 0
Current Assets 0.03 0.02 0.07 0.07 0.01
Total Assets 0.03 0.02 0.07 0.1 1.53
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 0 -0.01 0.06 0.02 0.1
Adjustment 0 0 0 0 0
Changes in Assets & Liabilities 0 0 -0.01 -0.01 0.01
Tax Paid 0 0 0 0 0
Operating Cash Flow 0 -0.01 0.04 0.02 0.11
Investing Cash Flow 0 0 0 0 1.32
Financing Cash Flow 0 0 0 0 -1.49
Net Cash Flow 0 -0.01 0.04 0.02 -0.06

Corporate Actions

Investors Details

PARTICULARS Jun 2021% Sep 2021% Dec 2021% Mar 2022% Jun 2022%
promoters 14.12 14.12 14.12 14.12 14.12
dharam chand jain 14.12 14.12 14.12 14.12 14.12
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 100.00 100.00 100.00 100.00 100.00
shubham garg 1.49 1.49 1.81 1.89 1.91
vinod k s 1.47 1.47 1.49 1.50 1.50
vizwise commerce private ... 2.24 2.24 2.24 2.24 2.24

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Welcure Drugs & Pharmaceuticals informs about notice of postal ballot 2 Apr 2024, 5:16PM Welcure Drugs&Pharma - Quaterly Results14 Feb 2024, 6:22PM Welcure Drugs & Pharmaceuticals informs about press release16 Nov 2023, 12:48PM Welcure Drugs & Pharmaceuticals submits certificate6 Oct 2023, 2:38PM Welcure Drugs&Pharma - Quaterly Results14 Aug 2023, 4:27PM Welcure Drugs & Pharmaceuticals informs about press release 13 Jul 2023, 2:50PM Welcure Drugs&Pharma - Quaterly Results11 Jul 2023, 6:52PM Welcure Drugs&Pharma - Quaterly Results11 Jul 2023, 6:52PM Welcure Drugs & Pharmaceuticals informs about compliances-certificate 11 Jan 2023, 1:26PM Welcure Drugs & Pharmaceuticals informs about board meeting outcome 8 Oct 2022, 4:38PM Welcure Drugs&Pharma - Quaterly Results8 Oct 2022, 3:49PM Welcure Drugs&Pharma - Quaterly Results8 Oct 2022, 3:49PM Welcure Drugs&Pharma - Quaterly Results8 Oct 2022, 3:49PM Welcure Drugs & Pharmaceuticals informs about appointment of CFO1 Sep 2022, 5:01PM Welcure Drugs & Pharmaceuticals informs about newspaper advertisement18 Jul 2022, 12:39PM Welcure Drugs&Pharma - Quaterly Results16 Jul 2022, 1:01PM Welcure Drugs&Pharma - Quaterly Results16 Jul 2022, 1:01PM Welcure Drugs&Pharma - Quaterly Results16 Jul 2022, 1:01PM Welcure Drugs & Pharmaceuticals informs about compliance certificate6 Jul 2022, 3:17PM Welcure Drugs & Pharmaceuticals informs about voting results28 Jun 2022, 12:00PM Welcure Drugs & Pharmaceuticals informs about trading window closure27 Jun 2022, 3:40PM Welcure Drugs & Pharmaceuticals informs about annual secretarial compliance report2 May 2022, 6:04PM Welcure Drugs & Pharmaceuticals informs about non-applicability of large entities2 May 2022, 12:45PM Welcure Drugs & Pharmaceuticals informs about newspaper advertisement16 Apr 2022, 1:59PM Welcure Drugs&Pharma - Quaterly Results15 Apr 2022, 3:12PM Welcure Drugs&Pharma - Quaterly Results15 Apr 2022, 3:12PM Welcure Drugs&Pharma - Quaterly Results15 Apr 2022, 3:12PM Welcure Drugs & Pharmaceuticals informs about outcome of board meeting22 Jan 2022, 3:18PM Welcure Drugs&Pharma - Quaterly Results22 Jan 2022, 12:33PM Welcure Drugs&Pharma - Quaterly Results22 Jan 2022, 12:33PM Welcure Drugs & Pharmaceuticals informs about newspaper publication26 Oct 2021, 2:46PM Welcure Drugs & Pharmaceuticals informs about certificate14 Oct 2021, 12:49PM Welcure Drugs & Pharmaceuticals informs about e-voting results13 Jul 2021, 1:42PM Welcure Drugs & Pharmaceuticals informs about outcome of board meeting 12 Jul 2021, 5:19PM Welcure Drugs & Pharmaceuticals informs about newspaper advertisement27 Apr 2021, 4:12PM Welcure Drugs & Pharmaceuticals informs about outcome of board meeting26 Apr 2021, 4:54PM Welcure Drugs & Pharmaceuticals informs about newspaper publication18 Jan 2021, 3:24PM Welcure Drugs & Pharmaceuticals informs about newspaper publication21 May 2020, 2:16PM Welcure Drugs & Pharmaceuticals informs about outcome of board meeting11 May 2020, 2:31PM Welcure Drugs and Pharmaceuticals informs about board meeting6 May 2020, 3:23PM

Welcure Drugs&Pharma Stock Price Analysis and Quick Research Report. Is Welcure Drugs&Pharma an attractive stock to invest in?

 

Stock investing requires careful analysis of financial data to find out the company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement. This can be time-consuming and cumbersome. An easier way to find out about a company's performance is to look at its financial ratios, which can help to make sense of the overwhelming amount of information that can be found in a company's financial statements.

Here are the few indispensable tools that should be a part of every investor’s research process.

  • PE ratio: - Price to Earnings' ratio, which indicates for every rupee of earnings how much an investor is willing to pay for a share. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Welcure Drugs&Pharma has a PE ratio of 601.234567901235 which is high and comparatively overvalued .

  • Share Price: - The current share price of Welcure Drugs&Pharma is Rs 4.87. One can use valuation calculators of ticker to know if Welcure Drugs&Pharma share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Welcure Drugs&Pharma has ROA of 12.5145977887453 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Welcure Drugs&Pharma has a Current ratio of 0.431071166544387 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Welcure Drugs&Pharma has a ROE of 12.6503478079898 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Welcure Drugs&Pharma has a D/E ratio of 0 which means that the company has low proportion of debt in its capital.

  • Inventory turnover ratio: - Inventory Turnover ratio is an activity ratio and is a tool to evaluate the liquidity of a company's inventory. It measures how many times a company has sold and replaced its inventory during a certain period of time. Welcure Drugs&Pharma has an Inventory turnover ratio of 0 which shows that the management is inefficient in relation to its Inventory and working capital management.

  • Sales growth: - Welcure Drugs&Pharma has reported revenue growth of -100 % which is poor in relation to its growth and performance.

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Welcure Drugs&Pharma for the current financial year is 0 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Welcure Drugs&Pharma is Rs 0 and the yield is 0 %.

Last Updated on:
Brief about Welcure Drugs&Pharma
X